Yip-Schneider, Michele T.Soufi, MazharCarr, Rosalie A.Flick, Katelyn F.Wu, HuangbingColgate, Cameron L.Schmidt, C. Max2019-12-132019-12-132019Yip-Schneider, M. T., Soufi, M., Carr, R. A., Flick, K. F., Wu, H., Colgate, C. L., & Schmidt, C. M. (2019). Performance of candidate urinary biomarkers for pancreatic cancer—Correlation with pancreatic cyst malignant progression? The American Journal of Surgery. https://doi.org/10.1016/j.amjsurg.2019.09.013https://hdl.handle.net/1805/21489Background Intraductal papillary mucinous neoplasms (IPMN) are precursors of pancreatic cancer. Potential biomarkers of IPMN progression have not been identified in urine. A few urinary biomarkers were reported to be predictive of pancreatic ductal adenocarcinoma (PDAC). Here, we seek to assess their ability to detect high-risk IPMN. Methods Urine was collected from patients undergoing pancreatic resection and healthy controls. TIMP-1(Tissue Inhibitor of Metalloproteinase-1), LYVE-1(Lymphatic Vessel Endothelial Receptor 1), and PGEM(Prostaglandin E Metabolite) levels were determined by ELISA and analyzed by Kruskal-Wallis. Results Median urinary TIMP-1 levels were significantly lower in healthy controls (n = 9; 0.32 ng/mg creatinine) compared to PDAC (n = 13; 1.95) but not significantly different between low/moderate-grade (n = 20; 0.71) and high-grade/invasive IPMN (n = 20; 1.12). No significant difference in urinary LYVE-1 was detected between IPMN low/moderate (n = 16; 0.37 ng/mg creatinine) and high/invasive grades (n = 21; 0.09). Urinary PGEM levels were not significantly different between groups. Conclusions Urinary TIMP-1, LYVE-1, and PGEM do not correlate with malignant potential of pancreatic cysts.enPublisher Policyintraductal papillary mucinous neoplasmpancreatic cystpancreatic cancerArticle